No Data
No Data
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $19
Express News | HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab Plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
Candel Therapeutics Shares Are Down Today: What's Going On?
Candel Therapeutics Shares Positive Survival Data for Investigational Immunotherapy in NSCLC | NASDAQ:CADL
Candel Therapeutics Reports Positive Phase 2a Trial Results